The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
FDA says shortage of GLP-1 drug tirzepatide is over
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
MedPage Today6d
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
FDA says tirzepatide shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
Medscape1d
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
The American Journal of Managed Care5d
Weight Loss Drug Tirzepatide Now Approved for Sleep Apnea in Adults With Obesity
The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
Hold Rating on Inspire Medical Systems Amid FDA Approval of Tirzepatide for OSA
Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...
GlobalData on MSN5d
FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation
The FDA declared the tirzepatide shortage over in October 2023, but a lawsuit by Outsourcing Facilities Association, a trade ...
TCTMD2d
Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.